Business Description
Hepion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US21234W2026
Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 70.75 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.03 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | -63.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.52 | |||||
| 9-Day RSI | 36.1 | |||||
| 14-Day RSI | 35.87 | |||||
| 6-1 Month Momentum % | -39.76 | |||||
| 12-1 Month Momentum % | -80.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.31 | |||||
| Quick Ratio | 3.31 | |||||
| Cash Ratio | 2.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.4 | |||||
| Shareholder Yield % | -0.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -178.8 | |||||
| ROA % | -129.2 | |||||
| ROIC % | -980.72 | |||||
| ROC (Joel Greenblatt) % | -31472.54 | |||||
| ROCE % | -161.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.26 | |||||
| Price-to-Tangible-Book | 1.26 | |||||
| EV-to-EBIT | 0.1 | |||||
| EV-to-EBITDA | 0.1 | |||||
| EV-to-FCF | 0.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.42 | |||||
| Price-to-Net-Cash | 1.78 | |||||
| Earnings Yield (Greenblatt) % | 1000 | |||||
| FCF Yield % | -511.75 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers